10320 Camino Santa Fe, Suite G
San Diego, CA 92121
Tel: 858.875.1900 Fax: 858.875.1999

DPYS Antibody (C-term) Blocking peptide
Synthetic peptide
Catalog # BP13434b

Specification

DPYS Antibody (C-term) Blocking peptide - Product Information

Primary Accession Q14117

DPYS Antibody (C-term) Blocking peptide - Additional Information

Gene ID 1807

Other Names
Dihydropyrimidinase, DHP, DHPase, Dihydropyrimidine amidohydrolase, Hydantoinase, DPYS

Target/Specificity
The synthetic peptide sequence used to generate the antibody AP13434b was selected from the C-term region of DPYS. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.

Format
Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.

Storage
Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C.

Precautions
This product is for research use only. Not for use in diagnostic or therapeutic procedures.

DPYS Antibody (C-term) Blocking peptide - Protein Information

Name DPYS

Function
Catalyzes the second step of the reductive pyrimidine degradation, the reversible hydrolytic ring opening of dihydropyrimidines. Can catalyze the ring opening of 5,6-dihydrouracil to N-carbamyl-alanine and of 5,6-dihydrothymine to N-carbamyl-amino isobutyrate.

Tissue Location
Liver and kidney.

DPYS Antibody (C-term) Blocking peptide - Protocols

Provided below are standard protocols that you may find useful for product applications.

- Blocking Peptides

DPYS Antibody (C-term) Blocking peptide - Images

DPYS Antibody (C-term) Blocking peptide - Background

Dihydropyrimidinase catalyzes the conversion of5,6-dihydrouracil to 3-ureidopropionate in pyrimidine metabolism.Dihydropyrimidinase is expressed at a high level in liver andkidney as a major 2.5-kb transcript and a minor 3.8-kb transcript.Defects in the DPYS gene are linked to dihydropyrimidinuria.

DPYS Antibody (C-term) Blocking peptide - References

Kim, H.Y., et al. BMB Rep 43(8):547-553(2010)van Kuilenburg, A.B., et al. Biochim. Biophys. Acta 1802 (7-8), 639-648 (2010) :Fidlerova, J., et al. Cancer Chemother. Pharmacol. 65(4):661-669(2010)Thomas, H.R., et al. Pharmacogenet. Genomics 18(1):25-35(2008)Thomas, H.R., et al. Pharmacogenet. Genomics 17(11):973-987(2007)